Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

Overview of attention for article published in Journal of Neurology, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs: 1 blog

twitter: 4 X users

Readers on

mendeley: 85 Mendeley

Summary Blogs X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 15,761 followers.

RT @reneroblesce: These findings indicated particular advantages of ALEMTUZUMAB compared to FINGOLIMOD in patients stopping NATALIZUMAB. W…

18 Nov 2018

Reply Repost Favourite

We heard similar data at ECTRIMS: #alemtuzumab is superior to #fingolimod after stopping natalizumab cessation." https://t.co/cTdZX63YiH #pubmed #feedly

18 Nov 2018

Reply Repost Favourite

These findings indicated particular advantages of ALEMTUZUMAB compared to FINGOLIMOD in patients stopping NATALIZUMAB. Washout time was 63 days (mean) for FTY vs. 91 days (mean) for ALEM https://t.co/YjQ2huFZIY https://t.co/X95k098Mry

18 Nov 2018

Reply Repost Favourite

Very useful paper to help sequencing of drugs. "Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation" https://t.co/j2vgy9UATb https://t.co/Mq5pc0p7pC

18 Nov 2018

Reply Repost Favourite